IDEAYA Biosciences, Inc. IDYA

Company Overview

IDEAYA Biosciences, Inc. is a publicly traded biotechnology company focused on the discovery and development of targeted therapies for cancer, with an emphasis on precision medicine and synthetic lethality. The company operates within the biotechnology and oncology drug development industries, applying molecular diagnostics and genetic insights to identify patient populations most likely to benefit from its therapies. IDEAYA’s core strategy centers on exploiting cancer-specific genetic vulnerabilities, particularly within DNA damage repair and related pathways.

Founded in 2015, IDEAYA Biosciences has evolved from an early-stage research organization into a clinical-stage oncology company with multiple internally discovered programs in human clinical trials. Its differentiated positioning lies in the integration of computational biology, functional genomics, and medicinal chemistry to systematically identify and drug synthetic lethal targets. The company generates no material commercial revenue as of the latest public disclosures and is primarily funded through equity financing and strategic collaborations.